Search Results

You are looking at 101 - 110 of 1,186 items for :

  • "screening" x
  • Refine by Access: All x
Clear All
Full access

Lung Cancer Screening: The Last 10 Years

Douglas E. Wood

For decades, experts advocated early detection of common cancers to improve chances for long-term survival and cure. Breast, colon, and prostate cancers all have established screening programs that are covered by insurers, embraced by physicians

Full access

Oncologic Science on the Move: Cervical Cancer Screening

Rodger J. Winn

Full access

Breast Cancer Screening and Diagnosis Clinical Practice Guidelines

The University of Alabama at Birmingham Comprehensive Cancer Center

The lifetime risk of a woman developing breast cancer has increased over the past 5 years in the United States: of every 7 women, 1 is at risk based on a life expectancy of 85 years. An estimated 214,640 new cases (212,920 women and 1,720 men) of breast cancer and 41,430 deaths (40,970 women and 460 men) from this disease will occur in the United States in 2006. However, mortality from breast cancer has decreased slightly, attributed partly to mammographic screening. Early detection and accurate diagnosis made in a cost-effective manner are critical to a continued reduction in mortality. These practice guidelines are designed to facilitate clinical decision making.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Colon Cancer Screening Continues as Pivotal to Cancer Prevention

Randall W. Burt

Colon cancer screening has been one of the great successes of cancer prevention. The decrease in colon cancer incidence and mortality in recent years is thought to be at least partly from the application and acceptance of screening. Colon cancer

Full access

Cancer Screening: When Is the Juice Worth the Squeeze?

Margaret Tempero

foolishly. I thought about this after reading a study in JAMA 1 regarding cancer screening in individuals with different life expectancies. The investigators, from the University of North Carolina, used a validated mortality index specific for the

Full access

Screening Contretemps: The Real Issue in the Mammogram Guideline Debate

Harold J. Burstein

The week of November 16, 2009, the U.S. Preventive Services Task Force (USPSTF) issued updated guidelines on breast cancer screening, with the controversial recommendation that women aged 40 to 49 years no longer undergo screening mammography

Full access

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer

Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer, and Ines Vaz-Luis

−/HER2−, and very uncommonly with HR+/HER2− breast cancer, had brain metastases on initial staging; of these, 6 were asymptomatic at the time of CNS screening: 5 of 6 and 1 of 6 patients had ≥5 and <5 brain metastases, respectively. Baseline TM testing

Full access

Abstracts From the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™

Population Best Practices in Implementation and Use of Clinical Practice Guidelines AB2015-9. Longitudinal Evaluation of a Colorectal Cancer Screening Measurement Model Bryan Loy, MD MBA; William T. Brooks, BS; Michael Yang, MD, MS; Laura E

Full access

Performance Status Restriction in Phase III Cancer Clinical Trials

Joseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, Timothy A. Lin, Austin B. Miller, Amit Jethanandani, Andres F. Espinoza, Dario Pasalic, Vivek Verma, Noam A. VanderWalde, Benjamin D. Smith, Grace L. Smith, C. David Fuller, Prajnan Das, Bruce D. Minsky, Claus Rödel, Emmanouil Fokas, Reshma Jagsi, Charles R. Thomas Jr, Ishwaria M. Subbiah, Cullen M. Taniguchi, and Ethan B. Ludmir

. Trials were subsequently screened for therapeutic, cancer-specific, phase III, randomized, multiarm trials in adult patients. Figure 1 presents the trial screening and eligibility criteria adopted in this study based on the PRISMA methodology. 17 Figure

Full access

Interpretation of Genetic Testing for Lynch Syndrome in Patients With Putative Familial Colorectal Cancer

Christina Rybak and Michael J. Hall

hereditary nonpolyposis colorectal cancer. Previously, an understanding of the workup of individuals suspected of having LS could be left to those specializing in genetics. Recently, screening of all patients with newly diagnosed CRC for LS independent of